Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). (Q34815054)

4 August 2017

title

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). (English)

1 reference

4 August 2017

1 reference

9

D L Porter

1 reference

4 August 2017

10

E A Stadtmauer

1 reference

4 August 2017

R Reshef

1

1 reference

4 August 2017

S Vardhanabhuti

2

1 reference

4 August 2017

M R Luskin

3

1 reference

4 August 2017

D F Heitjan

4

1 reference

4 August 2017

D Hadjiliadis

5

1 reference

4 August 2017

S Goral

6

1 reference

4 August 2017

K L Krok

7

1 reference

4 August 2017

L R Goldberg

8

1 reference

4 August 2017

D E Tsai

11

1 reference

4 August 2017

language of work or name

English

0 references

publication date

10 January 2011

1 reference

American Journal of Transplantation

4 August 2017

published in

1 reference

4 August 2017

volume

11

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

336-347

1 reference

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

The management of posttransplant lymphoproliferative disorder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Post-transplant lymphoproliferative disorder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Posttransplant lymphoproliferative disorder: significance of central nervous system involvement

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Persistence of the Epstein-Barr virus and the origins of associated lymphomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

A single-centre experience of post-renal transplant lymphoproliferative disorder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Epstein-Barr virus monitoring in paediatric renal transplant recipients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Clinical and pathological features of posttransplant lymphoproliferative disorders: influence on survival and response to treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Epstein-Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Treatment of PTLD with rituximab or chemotherapy

8 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Epstein-Barr virus infections in children after transplantation of the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Identification of prognostic factors in post-transplant lymphoproliferative disorders

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

26 October 2018

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2010.03387.X

Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079420

Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases

26 October 2018

1 reference

12 December 2020

Tonsil enlargement after liver transplantation in adults--reason enough for tonsillectomy? Two cases of tonsillar posttransplantation lymphoproliferative disease

1 reference

12 December 2020

CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation

1 reference

12 December 2020

Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment

1 reference

12 December 2020

Posttransplant lymphoproliferative disorder following pancreas transplantation

1 reference

12 December 2020

Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients

1 reference

12 December 2020

Retransplantation after post-transplant lymphoproliferative diseases (PTLD): when is it safe?

1 reference

12 December 2020

Management of lymphoproliferative disorders after cardiac transplantation

1 reference

12 December 2020

Aggressive treatment for postcardiac transplant lymphoproliferation

1 reference

12 December 2020

Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder

1 reference

12 December 2020

Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?

1 reference

12 December 2020

Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience

1 reference

12 December 2020

10.1111/J.1600-6143.2010.03387.X

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference